Held by: VTI VXF | Scroll to Statements |
Index | - | P/E | - | EPS (ttm) | -0.92 | Insider Own | 51.67% | Shs Outstand | 9.39M | Perf Week | 9.88% |
Market Cap | 31.13M | Forward P/E | - | EPS next Y | -0.53 | Insider Trans | 0.00% | Shs Float | 5.63M | Perf Month | 51.70% |
Income | -8.37M | PEG | - | EPS next Q | -0.17 | Inst Own | 2.06% | Short Float | 9.81% | Perf Quarter | -11.00% |
Sales | 4.94M | P/S | 6.30 | EPS this Y | 26.37% | Inst Trans | 242.11% | Short Ratio | 6.00 | Perf Half Y | 76.82% |
Book/sh | 0.47 | P/B | 5.70 | EPS next Y | 20.90% | ROA | -90.38% | Short Interest | 0.55M | Perf Year | 51.70% |
Cash/sh | 0.21 | P/C | 12.71 | EPS next 5Y | - | ROE | -112.11% | 52W Range | 0.95 - 3.62 | Perf YTD | 81.57% |
Dividend Est. | - | P/FCF | - | EPS past 5Y | -19.28% | ROI | -133.27% | 52W High | -26.24% | Beta | 2.99 |
Dividend TTM | - | Quick Ratio | 2.21 | Sales past 5Y | 13156.86% | Gross Margin | 25.24% | 52W Low | 179.64% | ATR (14) | 0.20 |
Dividend Ex-Date | - | Current Ratio | 2.22 | EPS Y/Y TTM | 6.02% | Oper. Margin | -169.31% | RSI (14) | 64.39 | Volatility | 9.51% 8.02% |
Employees | 75 | Debt/Eq | 0.28 | Sales Y/Y TTM | 86182.88% | Profit Margin | -169.42% | Recom | 1.00 | Target Price | 6.00 |
Option/Short | No / Yes | LT Debt/Eq | 0.19 | EPS Q/Q | -8.80% | Payout | - | Rel Volume | 1.30 | Prev Close | 2.53 |
Sales Surprise | 20.32% | EPS Surprise | -10.53% | Sales Q/Q | 261180.24% | Earnings | May 15 BMO | Avg Volume | 92.07K | Price | 2.67 |
SMA20 | 15.99% | SMA50 | 18.78% | SMA200 | 42.54% | Trades | Volume | 127,026 | Change | 5.53% |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
bioAffinity Technologies, Inc. operates as a development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The firm develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. The company was founded on March 26, 2014 and is headquartered in San Antonio, TX. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions withourpremium features. Real-time quotes, advancedvisualizations, backtesting, and much more.
Learn more about FINVIZ*Elite